Meet our SPARK Fellows
Introducing Cohort 7
Cohort 6
Maria Nagel, MD
Neurokinin-1 Receptor Antagonists as Antiviral Agents against Herpes Simplex Viruses
Email Address:MARIA.NAGEL@CUANSCHUTZ.EDU
Neurokinin-1 Receptor Antagonists as Antiviral Agents against Herpes Simplex Viruses
This project aims to address the devastating effects of Herpes Simplex Virus type 1 (HSV-1) infections, including herpes simplex encephalitis (HSE) and ocular HSV leading to blindness. Current treatments with acyclovir have limitations, including resistance development and intermittent shortages. The researchers propose repurposing neurokinin-1 receptor (NK-1R) antagonists, currently used as antiemetics, as antiviral drugs against HSV-1. In vitro studies show promising results with aprepitant reducing HSV-1 DNA in human astrocytes. The project will test the efficacy of aprepitant combined with acyclovir in murine models of HSE and ocular HSV, aiming to improve outcomes and reduce morbidity and mortality. The research team's expertise in HSV pathogenesis and established protocols strengthens the project's potential success. Collaborators: Andrew Bubak, PhD
Learn more about Dr. NagelCohort 5
Maria Nagel, MD
Neurokinin-1 Receptor Antagonists as Antiviral Agents against Herpes Simplex Viruses
Email Address:MARIA.NAGEL@CUANSCHUTZ.EDU
Neurokinin-1 Receptor Antagonists as Antiviral Agents against Herpes Simplex Viruses
This project aims to address the devastating effects of Herpes Simplex Virus type 1 (HSV-1) infections, including herpes simplex encephalitis (HSE) and ocular HSV leading to blindness. Current treatments with acyclovir have limitations, including resistance development and intermittent shortages. The researchers propose repurposing neurokinin-1 receptor (NK-1R) antagonists, currently used as antiemetics, as antiviral drugs against HSV-1. In vitro studies show promising results with aprepitant reducing HSV-1 DNA in human astrocytes. The project will test the efficacy of aprepitant combined with acyclovir in murine models of HSE and ocular HSV, aiming to improve outcomes and reduce morbidity and mortality. The research team's expertise in HSV pathogenesis and established protocols strengthens the project's potential success. Collaborators: Andrew Bubak, PhD
Learn more about Dr. NagelCohort 4
Maria Nagel, MD
Neurokinin-1 Receptor Antagonists as Antiviral Agents against Herpes Simplex Viruses
Email Address:MARIA.NAGEL@CUANSCHUTZ.EDU
Neurokinin-1 Receptor Antagonists as Antiviral Agents against Herpes Simplex Viruses
This project aims to address the devastating effects of Herpes Simplex Virus type 1 (HSV-1) infections, including herpes simplex encephalitis (HSE) and ocular HSV leading to blindness. Current treatments with acyclovir have limitations, including resistance development and intermittent shortages. The researchers propose repurposing neurokinin-1 receptor (NK-1R) antagonists, currently used as antiemetics, as antiviral drugs against HSV-1. In vitro studies show promising results with aprepitant reducing HSV-1 DNA in human astrocytes. The project will test the efficacy of aprepitant combined with acyclovir in murine models of HSE and ocular HSV, aiming to improve outcomes and reduce morbidity and mortality. The research team's expertise in HSV pathogenesis and established protocols strengthens the project's potential success. Collaborators: Andrew Bubak, PhD
Learn more about Dr. Nagel